|Bid||0.7576 x 3000|
|Ask||0.7600 x 1800|
|Day's Range||0.7351 - 0.7600|
|52 Week Range||0.6200 - 6.9800|
|Beta (3Y Monthly)||3.05|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.38|
Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...
TransEnterix, Inc. (NYSE American: TRXC) a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced the company’s Senhance Microlaparoscopy 3 mm instruments is a recipient of the 2019 Innovations of the Year award from the Society of Laparoendoscopic Surgeons (SLS). TransEnterix received the award at SLS’ Minimally Invasive Surgery Week 2019 (MISWeek 2019), September 4, in New Orleans, Louisiana.
TransEnterix, Inc. (NYSE American: TRXC) today announced that it has commenced an underwritten public offering of shares of its common stock. TransEnterix intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares in the offering are to be sold by TransEnterix.
TransEnterix, Inc. announced today that Todd M. Pope, President and Chief Executive Officer and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Wells Fargo Securities Research, Economics & Strategy 2019 Healthcare Conference in Boston, MA.
TransEnterix (TRXC) delivered earnings and revenue surprises of -12.50% and -29.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
TransEnterix, Inc. , a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the second quarter of 2019.
TransEnterix (TRXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Vislink Technologies, Inc. (NASDAQ: VISL ) ...
Transenterix (NYSE: TRXC) said Wednesday it's selling AutoLap’s assets to Great Belief International Limited for $47 million. The company also announced Great Belief International Limited is making an equity investment of $30 million In Transenterix’s common stock at $2.00 per share payable on or before Sept. 30. Transenterix is a medical device company.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
TransEnterix, Inc. announced today that Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will present at the Raymond James Life Sciences and Medtech Conference at The Lotte New York Palace in New York City.
TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced that it has received Japanese regulatory approval for the Senhance™ Surgical System. “Regulatory approval in Japan is a pivotal milestone for our company, as Japan is second only to the U.S. as the world’s largest surgical robotics market,” said Todd M. Pope, president and chief executive officer of TransEnterix.